Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Feb 26:13:17.
doi: 10.4103/abr.abr_67_23. eCollection 2024.

Toll-Like Receptor 4, 2, and Interleukin 1 Receptor Associated Kinase4: Possible Diagnostic Biomarkers in Myelodysplastic Syndrome Patients

Parvin Khalilian  1 , Nahid Eskandari  1   2 , Mohammad Jafar Sharifi  3 , Mohammad Soltani  1 , Pardis Nematollahi  4
Affiliations

Toll-Like Receptor 4, 2, and Interleukin 1 Receptor Associated Kinase4: Possible Diagnostic Biomarkers in Myelodysplastic Syndrome Patients

Parvin Khalilian et al. Adv Biomed Res. .

Abstract

Background: Myelodysplastic syndrome (MDS) is a clonal hematologic disorder that requires the integration of morphologic, cytogenetic, hematologic, and clinical findings for a successful diagnosis. Trying to find ancillary tests such as biomarkers improve the diagnosis process. Several studies showed that a disordered immune system is associated with MDS. The chronic activated innate immune system, particularly the Toll-like receptors (TLRs) pathway could be involved in the induction of the inflammation.

Materials and methods: In the present study, we investigated the expression of TLR2, TLR4, and IRAK4 in bone marrow (BM) of MDS patients, the leukemia group, and the healthy group. For this purpose, we assessed the expression of TLR2, TLR4, and IRAK4 by real time-PCR.

Results: In line with new findings, we demonstrated that the expression of TLR2, TLR4, and IRAK4 significantly increased in MDS BM compared with the healthy group. Moreover, IRAK4 expression raised significantly in MDS patients compared with other studied hematologic neoplasms. Also, the expression levels of TLR2 and TLR4 significantly increased in MDS in comparison to some studied non-MDS malignancies (P ˂ 0.05). Receiver operating characteristics (ROC) analysis and area under the curve (AUC) suggested that the expression of TLR2, TLR4, and IRAK4 (AUC = 0.702, AUC = 0.75, and AUC = 0.682, respectively) had acceptable diagnostic values to identify MDS from the other understudied leukemias.

Conclusion: Overall, the expression of TLR2, TLR4, and IRAK4 could be potential biomarkers for discriminating MDS from some hematologic disorders.

Keywords: IRAK4; TLR2; TLR4; myelodysplastic syndrome.

PubMed Disclaimer

Conflict of interest statement

There are no conflicts of interest.

Figures

Figure 1
Figure 1
Comparison of TLR2, TLR42, and IRAK4 gene expressions in BM cells of MDS patients and health controls by the quantitative reverse transcriptase-polymerase chain reaction. The healthy controls included five persons with normal bone marrow and no history of cancer. Error bars correspond to mean ± SEM; P ˂ 0.05 is significant. MDS: myelodysplastic syndrome
Figure 2
Figure 2
Quantification of TLR2 (a), TLR4 (b), and IRAK4 (c) in BM cells of MDS and non-MDS disorders by the quantitative reverse transcriptase-polymerase chain reaction. Error bars correspond to mean ± SEM; P ˂ 0.05 is significant. MDS: myelodysplastic syndrome, AML: Acute myeloid leukemia, ALL: Acute Lymphoblastic leukemia, CLL: Chronic Lymphoblastic leukemia, MM: Multiple myeloma
Figure 3
Figure 3
Receiver operating curve (ROC) analysis of TLR2, TLR4, and IRAK4 gene expression to determine diagnostic accuracy in differentiation of MDS patients with other hematologic disorders. AUC: area under the curve
See this image and copyright information in PMC

References

    1. Gangat N, Patnaik MM, Tefferi A. Myelodysplastic syndromes: Contemporary review and how we treat. Am J Hematol. 2016;91:76–89. - PubMed
    1. Weinberg OK, Hasserjian RP. The current approach to the diagnosis of myelodysplastic syndromes. Semin Hematol. 2019;56:15–21. - PubMed
    1. Matsuda A, Germing U, Jinnai I, Misumi M, Kuendgen A, Knipp S, et al. Difference in clinical features between Japanese and German patients with refractory anemia in myelodysplastic syndromes. Blood. 2005;106:2633–40. - PubMed
    1. Tinsley SM, Sutton SK, Thapa R, Lancet J, McMillan SC. Treatment choices: A quality of life comparison in acute myeloid leukemia and high-risk myelodysplastic syndrome. Clin Lymphoma Myeloma Leuk. 2017;17(S):S75–9. - PMC - PubMed
    1. Montalban-Bravo G, Garcia-Manero G. Myelodysplastic syndromes:2018 update on diagnosis, risk-stratification and management. Am J Hematol. 2018;93:129–47. - PubMed